A Phase II Study With Bendamustine Plus Brentuximab Vedotin in Hodgkin's Lymphoma and CD30+ Peripheral T-cell Lymphoma in First Salvage Setting: the BBV Regimen.
Phase of Trial: Phase II
Latest Information Update: 13 Sep 2017
At a glance
- Drugs Bendamustine (Primary) ; Brentuximab vedotin (Primary)
- Indications Lymphatic disorders
- Focus Therapeutic Use
- Acronyms FIL-BBV
- 02 Feb 2016 Status changed from not yet recruiting to recruiting as reported byClinicalTrials.gov.
- 21 Jul 2015 New trial record